Vaxil Bio Ltd
XTSX:VXL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/E
Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.
Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.
Valuation Scenarios
If P/E returns to its Industry Average (25.2), the stock would be worth CA$-0.44 (253% downside from current price).
| Scenario | P/E Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -16.5 | CA$0.29 |
0%
|
| Industry Average | 25.2 | CA$-0.44 |
-253%
|
| Country Average | 18.6 | CA$-0.33 |
-213%
|
Forward P/E
Today’s price vs future net income
Peer Comparison
| Market Cap | P/E | ||||
|---|---|---|---|---|---|
| CA |
V
|
Vaxil Bio Ltd
XTSX:VXL
|
1.2m CAD | -16.5 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
351.3B USD | 83.9 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
185.7B USD | 24.1 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
161.8B USD | 19 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
109.3B USD | 27.6 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | -533.6 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
79.4B USD | 17.6 | |
| NL |
|
argenx SE
XBRU:ARGX
|
41.2B EUR | 37.3 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | -61.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
62.7B AUD | 30.7 |
Market Distribution
| Min | 0 |
| 30th Percentile | 14.2 |
| Median | 18.6 |
| 70th Percentile | 29.3 |
| Max | 19 628.5 |
Other Multiples
Vaxil Bio Ltd
Glance View
Vaxil Bio Ltd. is an immunotherapy biotech company. The company is headquartered in Toronto, Ontario. The company went IPO on 2011-03-02. The firm is focused on targeting prominent cancer markers and infectious diseases. The Company’s lead products include ImMucin, VaxHit SPmAb2, SPmAb6 and MTbuVax. The ImMucin product is developing vaccine/treatment for COVID-19 and tuberculosis. The firm exploits the properties of signal peptide domains on crucial proteins to develop targeted therapies against cancer targets and infectious disease pathogens. The Company’s signal peptides induce a robust T and B-cell response across a range of varied human leukocyte antigen (HLA) subtypes, while acting as true, universal neoantigens. The Company’s peptide platform targets cells by educating or specifically activating the immune system to recognize and attack the affected cells. In addition, the Company’s mAb platform directly recognizes the target protein expressed on malignant cells and recruits other elements of the immune system to lyse those cells.
